Last updated: February 27, 2026
What excipients are used in Daurismo, and how do they influence formulation?
Daurismo (glasdegib) is an oral hedgehog pathway inhibitor approved by the FDA for newly diagnosed acute myeloid leukemia (AML) in certain patients. The drug’s formulation includes specific excipients that enhance stability, bioavailability, and patient tolerability.
Formulation Details:
- Active Ingredient: Glasdegib
- Excipients: Microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and others.
These excipients serve multiple roles: microcrystalline cellulose acts as a filler; croscarmellose sodium enhances disintegration; sodium lauryl sulfate functions as a surfactant to improve solubility; magnesium stearate functions as a lubricant.
How do excipient choices impact Daurismo’s formulation and patent landscape?
The selection and proportion of excipients influence the drug's patentability and commercial exclusivity. Patent strategies may include claims covering specific excipient combinations or manufacturing processes.
Differences in excipient composition could support potential formulation patents, delaying generic entry. Current formulations generally rely on standard excipients with long safety records, which can streamline regulatory pathways but may limit innovation claims.
What are the key considerations in developing alternative excipient strategies?
- Enhanced bioavailability: Using excipients like cyclodextrins or lipid-based carriers could improve absorption.
- Reduced side effects: Selecting excipients that minimize gastrointestinal irritation or allergic reactions.
- Extended shelf life: Incorporating stabilizers or antioxidants tailored to the drug’s stability profile.
Developers may explore proprietary excipients or novel delivery systems—such as liposomes, nanoparticles, or matrix tablets—to differentiate formulations and extend patent protections.
What commercial opportunities exist around excipient innovation for Daurismo?
- Formulation patents: Developing unique excipient combinations or delivery systems offers patent filing prospects.
- Contract manufacturing: Outsourcing excipient supply or formulation development to specialized firms with proprietary excipients.
- Regulatory pathways: Utilizing excipients with established safety profiles accelerates approval, enabling competitive market entry.
- Extended patent life: Innovating excipient strategies can create secondary patents, delaying biosimilar or generic competition.
Companies that innovate excipient profiles or delivery methods could position themselves as preferred suppliers or strategic partners, especially as biosimilars and generics enter the market.
How does the excipient landscape compare across similar oncology drugs?
| Drug |
Excipients Used |
Innovation Opportunities |
| Ivosidenib |
Microcrystalline cellulose, croscarmellose sodium |
Novel disintegration or dissolution enhancers |
| Midostaurin |
Lactose, microcrystalline cellulose, povidone |
Lipid-based formulations |
| Venetoclax |
Microcrystalline cellulose, croscarmellose sodium |
Targeted nanoparticle delivery |
While most oncology drugs rely on standard excipients, opportunities exist in replacing or augmenting these with advanced delivery systems to improve efficacy or tolerability.
Regulatory considerations for excipient modifications
Any change in excipient composition or quantity requires regulatory notification and, in some cases, supplemental filings. Demonstrating equivalent safety and bioavailability is critical for maintaining approval status. Proprietary excipients or delivery systems may necessitate additional safety data, prolonging development timelines.
Future trends in excipient development for Daurismo
- Biodegradable carriers: To sustain controlled release and improve patient compliance.
- Smart excipients: Responsive to physiological triggers to enhance targeted delivery.
- Personalized formulations: Tailoring excipient profiles based on genetic or metabolic patient profiles.
Key Takeaways
- Daurismo’s excipient profile uses standard, well-characterized excipients that support formulation stability and compliance with regulatory standards.
- Innovation in excipient formulation holds patent potential, especially through novel delivery systems or proprietary excipient combinations.
- Strategic partnerships and contract manufacturing can capitalize on excipient opportunities, creating barriers to generic competition.
- Regulatory pathways favor excipients with established safety, although modifications must comply with strict validation and notification processes.
- Future opportunities lie in advanced, targeted delivery systems that enhance efficacy and patient adherence.
FAQs
1. Can changing excipients in Daurismo formulations delay generic approval?
Yes. Developing formulations with novel or proprietary excipients can result in patent protections and extended exclusivity, delaying generic entry.
2. Are there safety concerns with alternative excipients for Daurismo?
All excipients must meet safety standards. Any new excipient or formulation change must undergo safety evaluation and regulatory approval.
3. How does excipient choice impact Daurismo’s bioavailability?
Excipients influence drug dissolution and absorption. Using surfactants or solubilizers can enhance bioavailability, potentially improving therapeutic outcomes.
4. What are potential patenting strategies related to excipients?
Patents may cover specific excipient combinations, delivery systems, manufacturing processes, or stable formulations optimized for Daurismo.
5. Are novel excipient delivery systems viable for existing drugs like Daurismo?
Yes. Delivery systems such as liposomes or nanoparticles can improve drug stability, reduce dosing frequency, and open new patent avenues.
References
-
U.S. Food and Drug Administration. (2022). Daurismo (glasdegib) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209561s000lbl.pdf
-
European Medicines Agency. (2021). Daurismo: Summary of Product Characteristics. Retrieved from https://www.ema.europa.eu/en/documents/product-information/daurismo-epar-product-information_en.pdf
-
Food and Drug Administration. (2017). Guidance for Industry: Excipients in Drug Products. FDA.
